Y
Y-mAbs Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2014 · IPO 2018
Clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients MoreLess
Y-mAbs Therapeutics was founded in 2015 by Thomas Gad, with a mission to develop innovative cancer treatments. The company focuses on creating antibody-based therapies, particularly targeting pediatric oncology.
In its early years, Y-mAbs concentrated on developing a robust pipeline of drug candidates. Their dedication to addressing unmet medical needs in cancer treatment quickly garnered attention in the biotech community.
A significant milestone for Y-mAbs came in September 2018, when the company went public on the NASDAQ under the ticker YMAB. The IPO was a pivotal moment, providing the necessary capital to advance their clinical trials and expand their research capabilities.
Y-mAbs has since made notable progress, particularly with its lead product candidates, which have shown promise in treating neuroblastoma, a rare pediatric cancer. The company's commitment to innovation and patient care continues to drive its research and development efforts.
Today, Y-mAbs stands as a testament to the impact of focused scientific research and the potential of antibody-based therapies in transforming cancer treatment. The journey of Y-mAbs Therapeutics highlights the importance of perseverance and innovation in the biopharmaceutical industry.
Talent graph
Y-mAbs Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Y-mAbs Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Y-mAbs Therapeutics has talent and traffic
team presence
across markets
Patent intelligence
$378k patent portfolio · 6 active families
Where Y-mAbs Therapeutics concentrates vs peers
Each axis is a top-10 topic across Y-mAbs Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Y-mAbs Therapeutics
An AI-synthesized read of the highest-engagement posts about Y-mAbs Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Y-mAbs Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.